These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7560811)

  • 21. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine.
    Raber W; Kmen E; Waldhäusl W; Vierhapper H
    Eur J Endocrinol; 2000 Feb; 142(2):117-24. PubMed ID: 10664518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
    Roti E; Robuschi G; Gardini E; Montermini M; Salvi M; Manfredi A; Gnudi A; Braverman LE
    Clin Endocrinol (Oxf); 1988 Mar; 28(3):305-14. PubMed ID: 3168311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on the T3 suppression test by the 24-hour thyroidal 131I uptake in patients with Graves' disease: comparison of the effects of propylthiouracil and methylmercaptoimidazole.
    Kobayashi I; Maruta S; Mori M; Ishii H; Ishihara H; Iriuchijima T; Takahashi M; Shimomura Y; Fukuda H
    Endocrinol Jpn; 1983 Aug; 30(4):491-7. PubMed ID: 6200318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A follow-up study of 85 patients with Graves' disease in remission who developed undetectable serum thyroid-stimulating hormone concentrations using sensitive TSH assays.
    Nagai K; Tamai H; Mukuta T; Morita T; Matsubayashi S; Kuma K; Nakagawa T
    Horm Res; 1991; 35(5):185-9. PubMed ID: 1802821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of simultaneous T3, T4, and TSH measurements for management of graves' disease in children.
    Golden MP; Kaplan SA; Lippe BM; Lee WN
    Pediatrics; 1977 May; 59(5):762-7. PubMed ID: 577011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the T3 suppression test with reference to the thyroidal 123I uptake in Graves' disease: comparison of 24-hour and 3-hour uptake.
    Yamaguchi T; Kobayashi I; Yamaguchi Y; Iwashita A; Inukai T; Ohshima K; Shimomura Y; Kobayashi S
    Endocrinol Jpn; 1990 Jun; 37(3):443-50. PubMed ID: 2253595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of Jiakangning Capsule on Thyroid Function and Akt/mTOR Signal Pathway of Graves' Disease Mice: an Experimental Study].
    Li QM; Wei JP; Li M; Meng SH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1119-24. PubMed ID: 26591370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
    Kruljac I; Solter D; Vrkljan AM; Solter M
    Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of total thyroxine-binding globulin deficiency with Graves' disease: fluctuations of plasma triiodothyronine/thyroxine ratio.
    Kamikubo K; Kojima N; Yamakita N; Miura K
    Jpn J Med; 1986 May; 25(2):186-90. PubMed ID: 3091890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J; Kuma K; Mozai T
    J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.